<DOC>
	<DOCNO>NCT01144663</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety meningococcal conjugate vaccine GSK134612 compare license vaccine MenC-CRM197 MenC-TT infant 2 month age . Pneumococcal conjugate vaccine DTPa-HBV-IPV/Hib vaccine co-administered .</brief_summary>
	<brief_title>Immunogenicity Safety Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal DTPa-HBV-IPV/Hib Vaccines</brief_title>
	<detailed_description>The study consist primary vaccination phase booster vaccination phase . The Protocol Posting update due protocol amendment 2 .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol ( e.g . completion diary card , return followup visit ) . A male female , include , 6 12 week ( 4290 day ) age time first vaccination . Written inform consent obtain parent ( ) guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period least 36 week . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Extended administration ( defined 14 day total ) immunosuppressant immunemodifying drug since birth . For corticosteroid , mean prednisone &gt; = 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Planned administration/ administration vaccine foreseen study protocol period start 30 day first dose vaccine ( ) 30 day last dose vaccine ( ) ( i.e . booster dose ) , exception rotavirus vaccine administer time study , accord national immunisation recommendation . MMR ( V ) vaccine , recommend national immunisation program , give last blood sample time point i.e . Visit 6 . Seasonal pandemic influenza vaccine give time study , accord Summary Product Characteristics national recommendation . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , Streptococcus pneumoniae , Neisseria meningitidis serogroups A , C , W135 Y exception vaccine first dose may give within first two week life accord national recommendation ( example hepatitis B BCG ) . History , intercurrent , diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b disease , pneumococcal and/or meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurologic disorder seizure ( history single , simple febrile seizure permit ) . Acute disease and/or fever time enrolment . ( Fever define temperature ≥ 37.5°C ( 99.5°F ) oral , axillary tympanic setting , ≥ 38.0°C ( 100.4°F ) rectal set ) . ( Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator ) . Administration immunoglobulins and/ blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Infants</keyword>
	<keyword>conjugate vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>co-administration</keyword>
</DOC>